Interaction of fucoidan with the proteins of the complement classical pathway

被引:63
作者
Tissot, B
Montdargent, B
Chevolot, L
Varenne, A
Descroix, S
Gareil, P
Daniel, R
机构
[1] Univ Evry Val Essonne, CNRS, UMR 8587, Lab Anal & Environm, F-91025 Evry, France
[2] ENSCP, CNRS, UMR 7575, Lab Electrochim & Chim Analyt, F-75231 Paris 05, France
来源
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS | 2003年 / 1651卷 / 1-2期
关键词
complement system; fucoidan; capillary electrophoresis; inhibitor; carbohydrate -protein interaction;
D O I
10.1016/S1570-9639(03)00230-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fucoidan inhibits complement by mechanisms that so far remain to be unraveled, and the objective of this work was to delineate the mode of inhibition by this sulfated polysaccharide. For that purpose, low molecular weight fractions of algal (Ascophyllum nodosum) fucoidan containing the disaccharide unit [-->3)-alpha-L-Fuc(2SO(3)(-))-->(1-->4)-alpha-L-Fuc(2,3diSO(3)(-))-(1-->](n) have been studied. Gel co-affinity electrophoresis and a new affinity capillary electrophoresis (ACE) method have been implemented to characterize fucoidan-complement protein complexes. Fucoidan binds C1q, likely to its collagen-like region through interactions involving lysine residues, and then prevents the association of the C1r(2)-C1s(2) subunit, required to form the fully active C1. In addition to C1q, fucoidan forms a complex with the protein C4 as observed by ACE. The fucoidan inhibits the first steps of the classical pathway activation that is of relevance in view of the proinflammatory effects of the subsequent products of the cascade. This study shows that a high level of inhibitory activity can be achieved with low molecular weight carbohydrate molecules and that the potential applicability of fucoidan oligosaccharides for therapeutic complement inhibition is worthy of consideration. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:5 / 16
页数:12
相关论文
共 53 条
[41]   Structure/function of C5 convertases of complement [J].
Rawal, N ;
Pangburn, MK .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2001, 1 (03) :415-422
[42]  
Reid Ken B., 2002, Trends in Immunology, V23, P115, DOI 10.1016/S1471-4906(01)02164-0
[43]   Specific inhibition of the classical complement pathway by C1q-binding peptides [J].
Roos, A ;
Nauta, AJ ;
Broers, D ;
Faber-Krol, MC ;
Trouw, LA ;
Drijfhout, JW ;
Daha, MR .
JOURNAL OF IMMUNOLOGY, 2001, 167 (12) :7052-7059
[44]   IDENTIFICATION OF MULTIPLE SITES OF INTERACTION BETWEEN HEPARIN AND THE COMPLEMENT-SYSTEM [J].
SAHU, A ;
PANGBURN, MK .
MOLECULAR IMMUNOLOGY, 1993, 30 (07) :679-684
[45]   Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics [J].
Sahu, A ;
Lambris, JD .
IMMUNOPHARMACOLOGY, 2000, 49 (1-2) :133-148
[46]  
SILVESTRI L, 1981, J BIOL CHEM, V256, P7383
[47]   IMPROVED 2,4,6-TRINITROBENZENESULFONIC ACID METHOD FOR DETERMINATION OF AMINES [J].
SNYDER, SL ;
SOBOCINSKI, PZ .
ANALYTICAL BIOCHEMISTRY, 1975, 64 (01) :284-288
[48]  
Speth C, 1999, WIEN KLIN WOCHENSCHR, V111, P378
[49]   Complement-endothelial cell interactions: pathophysiological implications [J].
Tedesco, F ;
Fischetti, F ;
Pausa, M ;
Dobrina, A ;
Sim, RB ;
Daha, MR .
MOLECULAR IMMUNOLOGY, 1999, 36 (4-5) :261-268
[50]   Capillary electrophoresis determination of the binding affinity of bioactive sulfated polysaccharides to proteins: study of the binding properties of fucoidan to antithrombin [J].
Varenne, A ;
Gareil, P ;
Colliec-Jouault, S ;
Daniel, R .
ANALYTICAL BIOCHEMISTRY, 2003, 315 (02) :152-159